KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Finished Goods (2017 - 2021)

Aquestive Therapeutics has reported Finished Goods over the past 5 years, most recently at $1.0 million for Q1 2021.

  • Quarterly results put Finished Goods at $1.0 million for Q1 2021, up 42.8% from a year ago — trailing twelve months through Mar 2021 was $1.0 million (up 42.8% YoY), and the annual figure for FY2020 was $544000.0, up 4.82%.
  • Finished Goods for Q1 2021 was $1.0 million at Aquestive Therapeutics, up from $544000.0 in the prior quarter.
  • Over the last five years, Finished Goods for AQST hit a ceiling of $1.3 million in Q2 2018 and a floor of $519000.0 in Q4 2019.
  • Median Finished Goods over the past 5 years was $1.0 million (2019), compared with a mean of $958461.5.
  • Biggest five-year swings in Finished Goods: plummeted 56.13% in 2019 and later skyrocketed 42.8% in 2021.
  • Aquestive Therapeutics' Finished Goods stood at $1.1 million in 2017, then grew by 11.18% to $1.2 million in 2018, then plummeted by 56.13% to $519000.0 in 2019, then rose by 4.82% to $544000.0 in 2020, then soared by 84.01% to $1.0 million in 2021.
  • The last three reported values for Finished Goods were $1.0 million (Q1 2021), $544000.0 (Q4 2020), and $858000.0 (Q3 2020) per Business Quant data.